Newborn Screening Saves Lives Reauthorization Act of 2025

Bill Number

H.R. 4709

Origin Chamber

House

Congress

119th Congress, Session 1

Policy Area

Health

Status

Introduced

Latest Action

2025-09-10: Forwarded by Subcommittee to Full Committee by Voice Vote.

Last Updated

2026-06-15T20:20:51Z

AI-Generated Summary

Purpose of the Legislation

The Newborn Screening Saves Lives Reauthorization Act of 2025 aims to extend and strengthen federal programs under the Public Health Service Act focused on screening newborns and children for heritable (genetic) disorders. It seeks to improve early detection, follow-up care, education, research, and data sharing to prevent or manage genetic diseases, ultimately saving lives and reducing long-term health costs.

Key Provisions

• Improved Screening and Follow-Up (Section 2): Updates grant purposes to include facilitating newborn screening, developing educational programs for parents and advocacy groups on counseling, testing, treatment, and long-term care (with audience-appropriate literacy levels and impact measurement), and enhancing follow-up services, including re-engaging patients who miss recommended care.
• Advisory Committee Enhancements (Section 3): Expands the role of the Advisory Committee on Heritable Disorders in Newborns and Children to include process improvements, creating public website materials on screening nominations (including data standards and technical assistance, with conflict-of-interest guidelines), and guidance on safe genetic testing for newborns with varied genetic conditions. Extends the committee's authorization through fiscal year 2030.
• Clearinghouse of Information (Section 4): Modifies the newborn screening information clearinghouse to complement (rather than just supplement) other federal efforts in sharing data.
• Laboratory Quality and Surveillance (Section 5): Authorizes funding for developing new screening tests, providing test materials, and enhancing performance evaluation services (including tools for better data analysis, interpretation, and best practices dissemination). Adds requirements for national surveillance, such as standardizing real-time data collection via electronic health records and linking state newborn screening programs with birth defects surveillance to track outcomes and connect families to services.
• Hunter Kelly Research Program (Section 6): Mandates (changes from optional) research on newborn screening technologies, focusing on conditions likely to be recommended for the uniform screening panel and piloting reliable tests for nationwide use. Requires funded entities to consult with state health departments where practical.
• Funding Authorizations (Section 7): Increases and extends appropriations for newborn screening grants and coordination activities from fiscal years 2015–2019 to 2026–2030, raising amounts from $11.9 million to $20.883 million for grants and from $8 million to $22.25 million for coordination.
• Ethics Guidance for Research (Section 8): Classifies research on non-identified newborn dried blood spots (leftover samples from heel-prick tests) as "secondary research" on non-identified biospecimens under federal regulations, simplifying ethical reviews for federally funded studies.

Significant Changes to Existing Law

• Reauthorization and Funding Boost: Extends programs through 2030 with substantially higher funding levels to support expanded activities.
• Expanded Duties and Mandates: Adds requirements for education, surveillance, research consultation, and public transparency (e.g., website materials on nomination processes); makes the Hunter Kelly research program mandatory.
• Technical and Procedural Updates: Refines grant approval criteria to emphasize infrastructure for adopting screening guidelines; updates surveillance to include real-time data and inter-program linkages; clarifies ethical rules for blood spot research to align with modern federal biospecimen regulations (e.g., 45 CFR 46.104(d)(4), which covers low-risk studies on anonymized samples).
• Wording Adjustments: Minor fixes for clarity, such as standardizing "follow-up" spelling and shifting from "supplant" to "complement" in information sharing.

Potential Impacts

• On Government Agencies: The Department of Health and Human Services (HHS) and Centers for Disease Control and Prevention (CDC) will manage increased funding and coordination, potentially improving national data systems and laboratory standards but requiring more resources for surveillance and advisory functions.
• On Citizens: Newborns and families will benefit from earlier detection of genetic disorders (affecting about 1 in 300 U.S. babies), better follow-up care, and accessible education, leading to timely treatments that prevent disabilities or death. Research on anonymized samples could accelerate new screening tests without privacy risks.
• On International Relations: Minimal direct impact, though provisions encouraging use of international data in nominations could foster global collaboration on genetic screening standards.

Main Stakeholders Affected

• Federal and State Agencies: HHS, CDC, and state health departments, which will handle grants, surveillance, and program implementation.
• Healthcare Providers and Laboratories: Doctors, nurses, and testing facilities benefiting from new tools, best practices, and genetic testing guidance.
• Families and Patients: Parents of newborns, children with heritable disorders, and advocacy/support groups gaining from education, follow-up services, and long-term outcome tracking.
• Researchers and Advocacy Organizations: Universities and groups involved in screening nominations, pilot studies, and ethical research on blood spots.

Notable Legal, Constitutional, or Political Implications

• Legal: Strengthens compliance with federal research ethics by classifying blood spot studies as low-risk secondary research, reducing administrative burdens on Institutional Review Boards (IRBs, ethics oversight committees) while protecting privacy through anonymization. No changes to core privacy laws like HIPAA.
• Constitutional: Aligns with the federal government's role in public health under the Commerce Clause; no apparent conflicts with individual rights, as it emphasizes voluntary education and non-identified research.
• Political: Bipartisan introduction (by representatives from both parties) suggests broad support for child health initiatives; increased funding could face budget debates but promotes equity in screening access across states.

This summary was generated by AI and may contain inaccuracies. Refer to the official source document for the authoritative text.

Sponsor

Rep. Morrison, Kelly [D-MN-3]

Cosponsors (6)

Rep. Simpson, Michael K. [R-ID-2], Rep. Schrier, Kim [D-WA-8], Rep. Langworthy, Nicholas A. [R-NY-23], Rep. Stanton, Greg [D-AZ-4], Rep. Lawler, Michael [R-NY-17], Rep. Auchincloss, Jake [D-MA-4]

Recent Actions

• 2025-09-10: Forwarded by Subcommittee to Full Committee by Voice Vote.
• 2025-09-10: Subcommittee Consideration and Mark-up Session Held
• 2025-09-10: Referred to the Subcommittee on Health.
• 2025-07-23: Referred to the House Committee on Energy and Commerce.
• 2025-07-23: Introduced in House
• 2025-07-23: Introduced in House

Bill Versions

• Newborn Screening Saves Lives Reauthorization Act of 2025 — issued 2025-07-23 — PDF (9 pages)